跳至主要内容
临床试验/NCT02702986
NCT02702986已完成1 期

Immunostimulating Interstitial Laser Thermotherapy in Patients With Locally Advanced Pancreatic Cancer: Results of a Prospective, Open, Non Comparative Study

Universita di Verona2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2016年2月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
10
试验地点
2
主要终点
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

研究概览

简要总结

10 Patients with Locally Advanced Pancreatic Cancer, no further responsive to neoadjuvant treatments but with a Stage-III disease will be submitted to imILT (Immunostimulating Interstitial Laser Thermotherapy). Safety and feasibility of imILT on LAPC will be evaluated as primary objective. Secondary objectives will be QoL after imILT, study of the immune reaction after imILT, oncological analysis of patients suffering from LAPC submitted to imILT.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of stage III locally advanced pancreatic cancer
  • No further neoadjuvant treatments are doable
  • Eastern Cooperative Oncology Group performance status < 1

排除标准

  • No other concomitant oncological treatments (hormonal, immunotherapies, etc)
  • Suffering from other neoplasms
  • Suffering from HIV
  • Suffering from autoimmune diseases
  • Concomitant medication with steroids

结局指标

主要结局

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

时间窗: Up to 24 months

次要结局

  • Disease specific survival (DSS)(Up to 24 months)
  • Progression free survival (PFS)(Up to 24 months)
  • The immunostimulating effects of imILT(Up to 24 months)
  • Overall Survival(Up to 24 months)

研究者

发起方
Universita di Verona
申办方类型
Other
责任方
Principal Investigator
主要研究者

Salvatore Paiella, MD

MD

Universita di Verona

研究点 (2)

Loading locations...

相似试验